Enzymatica AB (publ) (STO:ENZY)

Sweden flag Sweden · Delayed Price · Currency is SEK
2.640
-0.030 (-1.12%)
Apr 28, 2026, 5:24 PM CET
-24.57%
Market Cap 648.10M
Revenue (ttm) 53.90M
Net Income (ttm) -51.89M
Shares Out 242.74M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 82,095
Average Volume 152,612
Open 2.690
Previous Close 2.670
Day's Range 2.500 - 2.690
52-Week Range 1.600 - 3.580
Beta -0.27
RSI 48.18
Earnings Date Apr 14, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2007
Employees 20
Stock Exchange Nasdaq Stockholm
Ticker Symbol ENZY
Full Company Profile

Financial Performance

In 2025, Enzymatica AB's revenue was 53.90 million, an increase of 18.27% compared to the previous year's 45.58 million. Losses were -51.89 million, -2.42% less than in 2024.

Financial Statements

News

Enzymatica AB Transcript: Stora Aktiedagarna 2026

A new CEO with a strong entrepreneurial background is leading the international expansion of a scientifically validated cold treatment, ColdZyme, supported by robust clinical evidence and high customer satisfaction. The company is prioritizing partnerships and regulatory-driven market entry in Europe and beyond.

7 weeks ago - Transcripts

Enzymatica AB Transcript: Study Result

Recent independent studies show ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, with consistent results in both human and cell models. The product was well-tolerated, and findings are expected to apply to the general population.

1 year ago - Transcripts